Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

BACKGROUND: Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus. PATIENTS AND METHODS: Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Grünwald, V, Seidel, C, Fenner, M, Ganser, A, Busch, J, Weikert, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242587/
https://www.ncbi.nlm.nih.gov/pubmed/22033275
http://dx.doi.org/10.1038/bjc.2011.389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242587/
https://www.ncbi.nlm.nih.gov/pubmed/22033275
http://dx.doi.org/10.1038/bjc.2011.389

Ejemplares similares